NextCure(NXTC) - 2025 Q2 - Quarterly Results

Exhibit 99.1 NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results BELTSVILLE, Md. – August 7, 2025 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported second quarter 2025 financial results. "Our recent strategic acquisition of the global rights, excluding greater China, for SIM0505 targeting CDH6 (cadh ...